Novo Nordisk | NVO - Operating Expenses

Stock Price
50.30
Daily Change
-8.71 -14.76%
Monthly
-8.81%
Yearly
-39.15%
Q1 Forecast
56.42

Novo Nordisk reported DKK6.5B in Operating Expenses for its fiscal quarter ending in June of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Bausch Health Companies USD 1.96B 109M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Novartis USD 9.86B 115M Sep/2025
Novo Nordisk DKK 42.77B 3.48B Jun/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Prestige Brands USD 194.44M 16.67M Sep/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Zoetis USD 5.4B 3.94B Sep/2025